Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis

Journal of Investigative Dermatology

Volumn 136, Issue 8, 2016, Pages 1584-1591

  Yiu, Zenas Z N ^a,b   Exton, Lesley S ^c   Jabbar Lopez, Zarif ^d   Mohd Mustapa, M Firouz ^c   Samarasekera, Eleanor J ^e   Burden, A David ^f   Murphy, Ruth ^g   Owen, Caroline M ^h   Parslew, Richard ⁱ   Venning, Vanessa ^j   Ashcroft, Darren M ^b   Griffiths, Christopher E M ^a   Smith, Catherine H ^k   Warren, Richard B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c BRITISH ASSOCIATION OF DERMATOLOGISTS   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^f WESTERN INFIRMARY   (United Kingdom)

^g SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h ROYAL BLACKBURN HOSPITAL   (United Kingdom)

ⁱ ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^j OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; METHOTREXATE; PLACEBO; RETINOID; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; SECUKINUMAB; USTEKINUMAB;

ARTICLE; BIOLOGICAL THERAPY; DISEASE ASSOCIATION; HUMAN; INFECTION COMPLICATION; INFECTION RISK; META ANALYSIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; COMPLICATION; INFECTION; ODDS RATIO; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; HUMANS; INFECTION; METHOTREXATE; ODDS RATIO; PHOTOTHERAPY; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOIDS; RISK FACTORS; TIME FACTORS; USTEKINUMAB;

EID: 84992524346     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.03.035     Document Type: Article

References (46)

1. Asahina, A., Nakagawa, H., Etoh, T., Ohtsuki, M., Adalimumab, M.S.G., Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 37 (2010), 299–310.
2. Bachelez, H., van de Kerkhof, P.C., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.H., et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386 (2015), 552–561.
3. Blauvelt, A., Prinz, J.C., Gottlieb, A.B., Kingo, K., Sofen, H., Ruer-Mulard, M., et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 172 (2015), 484–493.
4. Bradburn, M.J., Deeks, J.J., Berlin, J.A., Russell Localio, A., Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26 (2007), 53–77.
5. Dommasch, E.D., Abuabara, K., Shin, D.B., Nguyen, J., Troxel, A.B., Gelfand, J.M., The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64 (2011), 1035–1050.
6. Galloway, J.B., Hyrich, K.L., Mercer, L.K., Dixon, W.G., Fu, B., Ustianowski, A.P., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50 (2011), 124–131.
7. Garcia-Doval, I., Carretero, G., Vanaclocha, F., Ferrandiz, C., Dauden, E., Sanchez-Carazo, J.L., et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 148 (2012), 463–470.
8. Garcia-Doval, I., Rustenbach, S.J., Stern, R., Dam, T.N., Cohen, A.D., Baker, C., et al. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol 169 (2013), 710–714.
9. Gordon, K.B., Duffin, K.C., Bissonnette, R., Prinz, J.C., Wasfi, Y., Li, S., et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 373 (2015), 136–144.
10. Gordon, K.B., Langley, R.G., Leonardi, C., Toth, D., Menter, M.A., Kang, S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006), 598–606.
11. Gottlieb, A.B., Evans, R., Li, S., Dooley, L.T., Guzzo, C.A., Baker, D., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004), 534–542.
12. Gottlieb, A.B., Leonardi, C., Kerdel, F., Mehlis, S., Olds, M., Williams, D.A., Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165 (2011), 652–660.
13. Gottlieb, A.B., Matheson, R.T., Lowe, N., Krueger, G.G., Kang, S., Goffe, B.S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003), 1627–1632.
14. Griffiths, C.E., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386 (2015), 541–551.
15. Griffiths, C.E., Strober, B.E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362 (2010), 118–128.
16. Igarashi, A., Kato, T., Kato, M., Song, M., Nakagawa, H., Japanese Ustekinumab Study G. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 39 (2012), 242–252.
17. Ioannidis, J.P., Evans, S.J., Gotzsche, P.C., O'Neill, R.T., Altman, D.G., Schulz, K., et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141 (2004), 781–788.
18. Iskandar, I.Y., Ashcroft, D.M., Warren, R.B., Yiu, Z.Z., McElhone, K., Lunt, M., et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol 173 (2015), 510–518.
19. Kalb, R.E., Fiorentino, D.F., Lebwohl, M.G., Toole, J., Poulin, Y., Cohen, A.D., et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol 151 (2015), 961–969.
20. Kimball, A.B., Leonardi, C., Stahle, M., Gulliver, W., Chevrier, M., Fakharzadeh, S., et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 171 (2014), 137–147.
21. Krueger, G.G., Langley, R.G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007), 580–592.
22. Landells, I., Marano, C., Hsu, M.C., Li, S., Zhu, Y., et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 73 (2015), 594–603.
23. Langley, R.G., Elewski, B.E., Lebwohl, M., Reich, K., Griffiths, C.E., Papp, K., et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 371 (2014), 326–338.
24. Leonardi, C.L., Kimball, A.B., Papp, K.A., Yeilding, N., Guzzo, C., Wang, Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371 (2008), 1665–1674.
25. Menter, A., Tyring, S.K., Gordon, K., Kimball, A.B., Leonardi, C.L., Langley, R.G., et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008), 106–115.
26. Nast, A., Jacobs, A., Rosumeck, S., Werner, R.N., Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol 135 (2015), 2641–2648.
27. Paller, A.S., Siegfried, E.C., Langley, R.G., Gottlieb, A.B., Pariser, D., et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358 (2008), 241–251.
28. Papp, K.A., Langley, R.G., Lebwohl, M., Krueger, G.G., Szapary, P., Yeilding, N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (2008), 1675–1684.
29. Papp, K.A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C.E., Nakanishi, A.M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005), 1304–1312.
30. Paul, C., Lacour, J.P., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 29 (2015), 1082–1090.
31. Puel, A., Picard, C., Cypowyj, S., Lilic, D., Abel, L., Casanova, J.L., Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines?. Curr Opin Immunol 22 (2010), 467–474.
32. Reich, K., Nestle, F.O., Papp, K., Ortonne, J.P., Evans, R., Guzzo, C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005), 1367–1374.
33. Rich, P., Sigurgeirsson, B., Thaci, D., Ortonne, J.P., Paul, C., Schopf, R.E., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168 (2013), 402–411.
34. Rychly, D.J., DiPiro, J.T., Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25 (2005), 1181–1192.
35. Saurat, J.H., Stingl, G., Dubertret, L., Papp, K., Langley, R.G., Ortonne, J.P., et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158 (2008), 558–566.
36. Singh, J.A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386 (2015), 258–265.
37. Strober, B.E., Crowley, J.J., Yamauchi, P.S., Olds, M., Williams, D.A., Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165 (2011), 661–668.
38. Taichman, D.B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P.W., Drazen, J.M., et al. Sharing clinical trial data—a proposal from the International Committee of Medical Journal Editors. N Engl J Med 374 (2016), 384–386.
39. Thaci, D., Blauvelt, A., Reich, K., Tsai, T.F., Vanaclocha, F., Kingo, K., et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73 (2015), 400–409.
40. Tsai, T.F., Ho, J.C., Song, M., Szapary, P., Guzzo, C., Shen, Y.K., et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63 (2011), 154–163.
41. Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006), 29–35.
42. van de Kerkhof, P.C., Segaert, S., Lahfa, M., Luger, T.A., Karolyi, Z., Kaszuba, A., et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 159 (2008), 1177–1185.
43. Watford, W.T., Hissong, B.D., Bream, J.H., Kanno, Y., Muul, L., O'Shea, J.J., Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202 (2004), 139–156.
44. Yang, H.Z., Wang, K., Jin, H.Z., Gao, T.W., Xiao, S.X., Xu, J.H., et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl) 125 (2012), 1845–1851.
45. Yoshida, K., Solomon, D.H., Kim, S.C., Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 11 (2015), 437–441.
46. Zhu, X., Zheng, M., Song, M., Shen, Y.K., Chan, D., Szapary, P.O., et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol 12 (2013), 166–174.